<p>根据 Axa S.A.在最近向证券交易委员会提交的 Form 13F 文件，该公司在第二季度增持了 Vertex Pharmaceuticals Incorporated（纳斯达克代码：VRTX - 免费报告）6.5% 的股份。这家机构投资者在此期间购买了额外的 10,477 股后，持有 171,270 股该制药公司的股票。Axa S.A.在最近的报告期末持有的 Vertex Pharmaceuticals 股份约占 0.07%，价值 76,249,000 美元。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
<ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
<p>其他对冲基金最近也对该公司的持仓进行了调整。Activest Wealth Management 在第一季度购买了价值约 25,000 美元的 Vertex Pharmaceuticals 新头寸。Clal Insurance Enterprises Holdings Ltd 在第一季度将其在 Vertex Pharmaceuticals 的股份增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 现在拥有 55 股该制药公司的股票，价值 27,000 美元，此前在上个季度又购买了 45 股。Access Investment Management LLC 在第二季度购买了价值 27,000 美元的 Vertex Pharmaceuticals 新头寸。Flaharty Asset Management LLC 在第一季度购买了价值 32,000 美元的 Vertex Pharmaceuticals 新股份。最后，Legacy Investment Solutions LLC 在第二季度购买了价值 29,000 美元的 Vertex Pharmaceuticals 新股份。目前，90.96% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Vertex Pharmaceuticals 股价下跌 3.0%</h2>
<p>纳斯达克：VRTX 周二开盘价为 442.04 美元。该公司的市值为 1,121.5 亿美元，市盈率为 31.17，贝塔值为 0.32。Vertex Pharmaceuticals Incorporated 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。该股票的 50 日简单移动平均线为 423.07 美元，200 日简单移动平均线为 425.36 美元。</p>
<ul>
<li>2025 年最佳生物技术股票推荐</li>
</ul>
<p>Vertex Pharmaceuticals（纳斯达克：VRTX - 获取免费报告）最近在 11 月 3 日星期一发布了季度财报。该制药公司报告季度每股收益为 4.80 美元，超出市场共识预期的 4.58 美元，超出 0.22 美元。该公司季度收入为 30.8 亿美元，而市场共识预期为 30.5 亿美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。与去年同期相比，该公司的收入增长了 11.0%。去年同期，该公司每股收益为 4.38 美元。整体来看，股票研究分析师预测 Vertex Pharmaceuticals Incorporated 在本财年将发布 15.63 美元的每股收益。</p>
<h2>分析师设定新目标价</h2>
<p>VRTX 最近成为多份研究报告的主题。巴克莱将 Vertex Pharmaceuticals 的目标价从 408.00 美元上调至 414.00 美元，并在 11 月 4 日的研究报告中给予该股票 “持平” 的评级。花旗集团将 Vertex Pharmaceuticals 的目标价从 550.00 美元上调至 575.00 美元，并在 10 月 2 日的研究报告中给予该股票 “买入” 的评级。Leerink Partners 将 Vertex Pharmaceuticals 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 9 月 25 日的研究报告中将该公司的目标价从 458.00 美元下调至 456.00 美元。摩根大通将 Vertex Pharmaceuticals 的目标价从 517.00 美元上调至 530.00 美元，并在 10 月 8 日的研究报告中给予该公司 “增持” 的评级。最后，Stifel Nicolaus 将 Vertex Pharmaceuticals 的目标价从 455.00 美元下调至 445.00 美元，并在 11 月 4 日的研究报告中对该股票设定了 “持有” 的评级。有两位分析师给予该股票 “强烈买入” 评级，十六位给予 “买入” 评级，十位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 495.53 美元。</p>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p><strong>阅读我们关于 VRTX 的最新报告</strong></p>
<h2>Vertex Pharmaceuticals 内部活动</h2>
<p>在其他新闻中，执行副总裁 Charles F. Wagner, Jr.在 12 月 3 日星期三出售了 14,000 股该股票。该股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。交易后，该执行副总裁持有 37,725 股公司股票，价值约为 17,202,600 美元。这代表其持仓减少了 27.07%。该交易已在向证券交易委员会的文件中披露，您可以通过此链接访问。此外，董事长 Jeffrey M. Leiden 在 12 月 3 日星期三出售了 63,781 股 Vertex Pharmaceuticals 股票。该股票以平均价格 449.20 美元出售，总价值为 28,650,425.20 美元。出售完成后，董事长持有 24,026 股公司股票，价值 10,792,479.20 美元。该交易使其持股减少了 72.64%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 151,073 股公司股票，价值 67,326,816 美元。0.20% 的股票由内部人士持有。</p>
<h2>Vertex Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>在 52 周高点盈利交易股票</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
<p><strong>想看看其他对 VRTX 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取 Vertex Pharmaceuticals Incorporated（NASDAQ:VRTX - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>Axa S.A. 在第二季度将其在 Vertex Pharmaceuticals 的股份增加了 6.5%，目前持有 171,270 股，价值 7625 万美元。分析师们为 Vertex 设置了新的价格目标，花旗集团将其目标提高至 575 美元，摩根大通则提高至 530 美元。该股票的平均评级为 “适度买入”，共识价格目标为 495.53 美元。内部人士活动包括执行副总裁 Charles Wagner 出售了 14,000 股</p>

<p>Axa S.A. grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 6.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 171,270 shares of the pharmaceutical company's stock after purchasing an additional 10,477 shares during the period. Axa S.A. owned approximately 0.07% of Vertex Pharmaceuticals worth $76,249,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据 Axa S.A.在最近向证券交易委员会提交的 Form 13F 文件，该公司在第二季度增持了 Vertex Pharmaceuticals Incorporated（纳斯达克代码：VRTX - 免费报告）6.5% 的股份。这家机构投资者在此期间购买了额外的 10,477 股后，持有 171,270 股该制药公司的股票。Axa S.A.在最近的报告期末持有的 Vertex Pharmaceuticals 股份约占 0.07%，价值 76,249,000 美元。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 警报：</p>
</div><ul>
<li>How Royalty Pharma Prints Cash Without Biotech's Biggest Risks</li>
</ul>
<div class="lb-trans"><ul>
<li>Royalty Pharma 如何在没有生物技术最大风险的情况下盈利</li>
</ul>
</div><p>Other hedge funds also recently made changes to their positions in the company. Activest Wealth Management purchased a new position in Vertex Pharmaceuticals during the 1st quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 45 shares during the last quarter. Access Investment Management LLC purchased a new position in shares of Vertex Pharmaceuticals in the second quarter valued at $27,000. Flaharty Asset Management LLC bought a new stake in Vertex Pharmaceuticals in the first quarter worth $32,000. Finally, Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at $29,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他对冲基金最近也对该公司的持仓进行了调整。Activest Wealth Management 在第一季度购买了价值约 25,000 美元的 Vertex Pharmaceuticals 新头寸。Clal Insurance Enterprises Holdings Ltd 在第一季度将其在 Vertex Pharmaceuticals 的股份增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 现在拥有 55 股该制药公司的股票，价值 27,000 美元，此前在上个季度又购买了 45 股。Access Investment Management LLC 在第二季度购买了价值 27,000 美元的 Vertex Pharmaceuticals 新头寸。Flaharty Asset Management LLC 在第一季度购买了价值 32,000 美元的 Vertex Pharmaceuticals 新股份。最后，Legacy Investment Solutions LLC 在第二季度购买了价值 29,000 美元的 Vertex Pharmaceuticals 新股份。目前，90.96% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Vertex Pharmaceuticals Trading Down 3.0%</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 股价下跌 3.0%</h2>
</div><p>NASDAQ:VRTX opened at $442.04 on Tuesday. The company has a market cap of $112.15 billion, a price-to-earnings ratio of 31.17 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The stock has a fifty day simple moving average of $423.07 and a 200-day simple moving average of $425.36.</p>
<div class="lb-trans"><p>纳斯达克：VRTX 周二开盘价为 442.04 美元。该公司的市值为 1,121.5 亿美元，市盈率为 31.17，贝塔值为 0.32。Vertex Pharmaceuticals Incorporated 的 12 个月低点为 362.50 美元，12 个月高点为 519.68 美元。该股票的 50 日简单移动平均线为 423.07 美元，200 日简单移动平均线为 425.36 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物技术股票推荐</li>
</ul>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping the consensus estimate of $4.58 by $0.22. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Vertex Pharmaceuticals had a net margin of 31.35% and a return on equity of 23.51%. The firm's revenue was up 11.0% compared to the same quarter last year. During the same quarter last year, the firm posted $4.38 EPS. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克：VRTX - 获取免费报告）最近在 11 月 3 日星期一发布了季度财报。该制药公司报告季度每股收益为 4.80 美元，超出市场共识预期的 4.58 美元，超出 0.22 美元。该公司季度收入为 30.8 亿美元，而市场共识预期为 30.5 亿美元。Vertex Pharmaceuticals 的净利润率为 31.35%，股本回报率为 23.51%。与去年同期相比，该公司的收入增长了 11.0%。去年同期，该公司每股收益为 4.38 美元。整体来看，股票研究分析师预测 Vertex Pharmaceuticals Incorporated 在本财年将发布 15.63 美元的每股收益。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>VRTX has been the subject of a number of recent research reports. Barclays lifted their price objective on shares of Vertex Pharmaceuticals from $408.00 to $414.00 and gave the stock an &#34;equal weight&#34; rating in a research note on Tuesday, November 4th. Citigroup boosted their price objective on Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, October 2nd. Leerink Partners upgraded Vertex Pharmaceuticals from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and decreased their price objective for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. JPMorgan Chase &amp; Co. raised their price objective on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the company an &#34;overweight&#34; rating in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus cut their target price on Vertex Pharmaceuticals from $455.00 to $445.00 and set a &#34;hold&#34; rating on the stock in a research report on Tuesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $495.53.</p>
<div class="lb-trans"><p>VRTX 最近成为多份研究报告的主题。巴克莱将 Vertex Pharmaceuticals 的目标价从 408.00 美元上调至 414.00 美元，并在 11 月 4 日的研究报告中给予该股票 “持平” 的评级。花旗集团将 Vertex Pharmaceuticals 的目标价从 550.00 美元上调至 575.00 美元，并在 10 月 2 日的研究报告中给予该股票 “买入” 的评级。Leerink Partners 将 Vertex Pharmaceuticals 的评级从 “市场表现” 上调至 “跑赢大盘”，并在 9 月 25 日的研究报告中将该公司的目标价从 458.00 美元下调至 456.00 美元。摩根大通将 Vertex Pharmaceuticals 的目标价从 517.00 美元上调至 530.00 美元，并在 10 月 8 日的研究报告中给予该公司 “增持” 的评级。最后，Stifel Nicolaus 将 Vertex Pharmaceuticals 的目标价从 455.00 美元下调至 445.00 美元，并在 11 月 4 日的研究报告中对该股票设定了 “持有” 的评级。有两位分析师给予该股票 “强烈买入” 评级，十六位给予 “买入” 评级，十位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 495.53 美元。</p>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p><strong>Read Our Latest Report on VRTX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 VRTX 的最新报告</strong></p>
</div><h2>Insider Activity at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 内部活动</h2>
</div><p>In other news, EVP Charles F. Wagner, Jr. sold 14,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $456.00, for a total transaction of $6,384,000.00. Following the transaction, the executive vice president owned 37,725 shares of the company's stock, valued at approximately $17,202,600. This represents a 27.07% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, Chairman Jeffrey M. Leiden sold 63,781 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $449.20, for a total value of $28,650,425.20. Following the completion of the sale, the chairman owned 24,026 shares of the company's stock, valued at $10,792,479.20. The trade was a 72.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 151,073 shares of company stock worth $67,326,816. 0.20% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，执行副总裁 Charles F. Wagner, Jr.在 12 月 3 日星期三出售了 14,000 股该股票。该股票以平均价格 456.00 美元出售，总交易额为 6,384,000.00 美元。交易后，该执行副总裁持有 37,725 股公司股票，价值约为 17,202,600 美元。这代表其持仓减少了 27.07%。该交易已在向证券交易委员会的文件中披露，您可以通过此链接访问。此外，董事长 Jeffrey M. Leiden 在 12 月 3 日星期三出售了 63,781 股 Vertex Pharmaceuticals 股票。该股票以平均价格 449.20 美元出售，总价值为 28,650,425.20 美元。出售完成后，董事长持有 24,026 股公司股票，价值 10,792,479.20 美元。该交易使其持股减少了 72.64%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 151,073 股公司股票，价值 67,326,816 美元。0.20% 的股票由内部人士持有。</p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Vertex Pharmaceuticals</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑对消费者健康的启示</li>
<li>在 52 周高点盈利交易股票</li>
<li>2026 年最有可能拆分的三只股票</li>
<li>三只提供优厚股息收益的天然气股票</li>
<li>ChargePoint 的复苏故事：为什么这只电动车股票再次充满活力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding VRTX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 VRTX 感兴趣的对冲基金持有哪些股票吗？</strong> 访问 HoldingsChannel.com，获取 Vertex Pharmaceuticals Incorporated（NASDAQ:VRTX - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

安盛股份有限公司购买了福泰制药公司（Vertex Pharmaceuticals Incorporated）的 10,477 股股票 $VRTX